Johnson & Johnson said Thursday it will pay $850 million in cash for Proteologix, a relatively unknown private biotech working on treatments for immune-mediated diseases, including the crowded field of atopic dermatitis.
The deal is relatively small compared to J&J’s recent M&A activity, and it’s quite early: Proteologix’s lead asset is “ready to enter Phase 1,” according to a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.